Smarter Braking for Electric Travel Trailers

SHANGHAI, Oct. 30, 2026 /PRNewswire/ -- As electric travel trailers move toward heavier loads and more diverse travel scenarios, changing loads are creating new challenges for the braking system. During emergency braking or long descents, poorly coordinated braking between the tow vehicle and trailer can cause the trailer to push the tow vehicle forward when trailer braking is insufficient, or pull it back when trailer braking is excessive. Beyond longer stopping distances, this can lead to vehicle sway and fishtailing.

Stability is also a concern during lane changes or sharp steering maneuvers, when trailer sway can escalate into uncontrollable sway, increasing the risk of loss of control or rollover. Additionally, for electric travel trailers equipped with regenerative braking, maintaining smooth and consistent deceleration as regenerative braking capability decreases presents another challenge for precise braking force control.

To address these challenges, LEEKR Technology, a China-based intelligent chassis solutions provider, offers its DHB-P (Two-box Decoupled Hydraulic Brake-by-Wire System). Combining full hydraulic decoupling with active brake pressure generation, the system delivers more responsive, coordinated braking across varying loads and driving conditions. By integrating with the vehicle control system, it enables more intelligent braking control, helping electric travel trailer OEMs improve braking performance and deliver a safer, smoother driving experience.

According to data published by the RV Industry Association (RVIA) in the United States and the Caravan Industry Association of Australia (CIAA), U.S. shipments of towable RVs reached approximately 306,000 units in 2025, while Australia had more than 817,000 registered towable RVs as of January 2025. This substantial market base points to significant potential for smarter braking technologies in both countries.

Building on extensive mass-production validation experience and mature automotive-grade technology in China's passenger vehicle market, LEEKR Technology is extending its automotive-grade brake-by-wire technology to smart towable RVs. Its DHB-P brake-by-wire system has entered mass production for the world's first self-propelled travel trailer, which features its own electric drive system,  and has been deployed in RV projects in North America, Australia and China.

Smarter Braking for Electric Travel Trailers

The DHB-P brake-by-wire system adjusts hydraulic brake pressure based on vehicle control commands to meet varying braking demands under different load and road conditions. This helps improve braking coordination between the trailer and tow vehicle, reducing unwanted pushing and pulling during deceleration.

For electric trailers equipped with regenerative braking, DHB-P provides hydraulic braking support when regenerative braking force decreases. Working with the vehicle's control system, it helps maintain smooth, consistent deceleration.

Designed for OEM integration, the DHB-P brake-by-wire system features a compact design and standardized interfaces for easier installation and vehicle integration. The system can also integrate an Electronic Parking Brake (EPB) based on project requirements, providing greater configuration flexibility across different vehicle platforms and helping OEMs reduce integration costs.

Advanced Braking for Evolving OEM Needs

For OEMs seeking advanced braking and stability control to address trailer sway and the risk of loss of control, LEEKR Technology offers the IHB-P (One-box Integrated Intelligent Braking System),  which integrates ebooster (DHB-P) and ESC(electronic stability control) into a single unit. Working with vehicle control systems, the solution supports ABS(Anti-lock Braking System) to help prevent wheel lockup during braking and  ASC(Active Sway Control System) to mitigate trailer sway during lane changes and sharp steering, helping avoid fishtailing and rollover while enhancing braking control and towing stability.

For more information about LEEKR Technology's intelligent braking solutions, visit the company's official website: www.leekr-chassis.com.

About Leekr Technology

Leekr Technology is a leading provider of system-level intelligent chassis solutions, with independently developed capabilities spanning brake-by-wire, intelligent steering, chassis domain control, and other core technologies. The company serves leading automakers worldwide, with a growing presence in the United States, South Africa, Türkiye, and Southeast Asia. Beyond intelligent vehicles, it is expanding into emerging mobility applications, including robotaxi, autonomous delivery, autonomous logistics, autonomous sanitation vehicle, and smart travel trailers. For more information, visit: www.leekr-chassis.com.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Smarter Braking for Electric Travel Trailers

BOSTON, , Oct. 31, 2026 /PRNewswire/ -- Dr. Yang Liu, Director of Medicinal Chemistry at Revolution Medicines, Inc., and Dr. Kristof Pota, Senior Scientist, visited Medicilon's Nanhui R&D Center. Dr. Maosheng Duan, President of Medicilon's Drug Discovery and Pharmaceutical Research Divisions, Dr. Jian Wang, Vice President of Medicilon, and their team welcomed them. The two parties held in-depth discussions on project progress, data transfer, and strategic priorities for the coming year. During the visit, Medicilon presented Revolution Medicines with the "Excellence in Client Partnership Award," recognizing the substantial clinical value of the company's pioneering pan-KRAS drug discovery and development. The award also honors years of joint effort, mutual trust, and shared success by both R&D teams, setting an outstanding example of bilateral collaboration.

A Three-Year Partnership Built on a Trusted R&D Model

Over the past three years, Medicilon's FTE team has worked closely with Revolution Medicines to tackle R&D technical challenges, consistently prioritizing client needs and focusing on the single objective of efficiently delivering high-quality molecules. This partnership has established a model of mutual trust and robust CRO–client collaboration.

At the award ceremony, Dr. Duan commended Revolution Medicines for its pioneering work in advancing KRAS—a target once deemed "undruggable"—and congratulated the company on the U.S. FDA's August 2026 approval of the NDA for Daraxonrasib for metastatic pancreatic cancer. This milestone offers new hope for pancreatic cancer patients and delivers significant clinical value. The Excellence in Client Partnership Award recognizes the trust, dedication, and achievements of both teams over more than three years of collaboration, reflecting Medicilon's confidence in a deeper, long-term partnership.

In-Depth Discussions Explore New Collaboration Opportunities

During the discussions, Dr. Wang outlined Medicilon's growth and its integrated R&D platform spanning target discovery to IND submission. Medicilon's quality system meets international standards and holds NMPA, OECD GLP, FDA GLP, and AAALAC accreditation. Its advanced platforms support ADC/AOC, TPD, RIPTAC, RNAi, and peptide programs. Both parties discussed cross-regional data transfer, project management, future collaboration, and ways to enhance cross-border R&D efficiency.

Laboratory Tour

Subsequently, Drs. Liu and Pota toured Medicilon's R&D laboratories, visiting the chemistry and oligonucleotide labs as well as the API and preclinical research facilities, gaining firsthand insight into Medicilon's R&D infrastructure and quality management system.

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

Medicilon Presents Revolution Medicines with the "Excellence in Client Partnership Award"